Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

  1. Garcia-Sanz, R.
  2. Sureda, A.
  3. De La Cruz, F.
  4. Canales, M.
  5. Gonzalez, A.P.
  6. Pinana, J.L.
  7. Rodriguez, A.
  8. Gutierrez, A.
  9. Domingo-Domenech, E.
  10. Sanchez-Gonzalez, B.
  11. Rodriguez, G.
  12. Lopez, J.
  13. Moreno, M.
  14. Rodriguez-Salazar, M.J.
  15. Jimenez-Cabrera, S.
  16. Caballero, M.D.
  17. Martinez, C.
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2019

Alea: 30

Zenbakia: 4

Orrialdeak: 612-620

Mota: Artikulua

DOI: 10.1093/ANNONC/MDZ009 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus